Lidofast (Lidocaine Hydrochloride)

Lidofast (lidocaine hydrochloride) is used within the local anesthetic pathway to produce reversible loss of sensation in targeted tissues.

• Minor surgical procedures: provides localized numbness to facilitate surgery.
• Dental procedures: numbs oral tissues to reduce pain during treatment.
• Superficial skin procedures: relieves pain during minor skin interventions such as biopsies or laser therapy.

• Lidocaine hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing the influx of sodium ions required for depolarisation. This inhibition stops the initiation and propagation of nerve impulses, resulting in a reversible loss of sensation in the area where the drug is applied.

Lidofast may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Burning or stinging at the application site.
• Tingling or numbness beyond the intended area.
• Redness or mild swelling of the skin.
• Dizziness or light‑headedness.
• Headache.
• Nausea.

Serious or Rare Side Effects

• Allergic reaction (rash, itching, swelling, bronchospasm).
• Systemic toxicity presenting as seizures or cardiac arrhythmia.
• Methemoglobinemia.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Respiratory depression.
• Cardiovascular collapse.

Before using Lidofast, consider the following safety measures.

• Allergy assessment: verify no known hypersensitivity to lidocaine or amide‑type anesthetics.
• Application area: limit use to intact skin or mucosa; avoid broken skin to reduce systemic absorption.
• Dosage limit: adhere to the recommended maximum dose for the specific formulation.
• Concomitant medications: exercise caution when combined with other local anesthetics or agents affecting cardiac conduction.
• Patient monitoring: observe for signs of central nervous system or cardiovascular toxicity during extensive use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lidofast can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase plasma lidocaine levels and toxicity risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can reduce lidocaine metabolism.
• Concurrent use of other local anesthetics: additive neuro‑cardiac toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask early signs of lidocaine toxicity.
• Loop diuretics (e.g., furosemide): may alter protein binding and increase free drug.
• General anesthetics (e.g., propofol, inhalational agents): may potentiate central nervous system depression.